Biotech Leaders Urge President Trump and Congress to Preserve DACA




To:       President Donald J. Trump

CC:      Speaker Paul Ryan; Leader Nancy Pelosi; Leader Mitch McConnell; Leader Charles E.
             Schumer; Members of the Senate; and, Members of the House of Representatives

From:   Leaders in the Biotechnology Industry

Re:       Preserve the Deferred Action for Childhood Arrivals (DACA) Program

Dear President Trump:

We, the 185 signatories to this letter, are entrepreneurs and business leaders in the Biotechnology Industry. We are deeply concerned about new developments in immigration policy that threaten the future of young undocumented immigrants brought to America as children. We ask you to reconsider your decision to rescind the DACA program.

The DACA program, which allows nearly 800,000 Dreamers the basic opportunity to work and study without the threat of deportation, is in jeopardy. All DACA recipients grew up in America, registered with our government, submitted to extensive background checks, and are diligently giving back to our communities and paying income taxes. More than 97 percent are in school or in the workforce, 5 percent started their own business, 65 percent have purchased a vehicle, and 16 percent have purchased their first home. At least 72 percent of the top 25 Fortune 500 companies count DACA recipients among their employees.

Unless we act now to preserve the DACA program, all 780,000 hardworking young people will lose their ability to work legally in this country, and every one of them will be at risk of deportation. Our economy would lose $460.3 billion from the national GDP and $24.6 billion in Social Security and Medicare tax contributions.

We call on you, President Trump, to reverse your decision and preserve the DACA program. We call on Congress to pass the bipartisan DREAM Act or legislation that provides these young people raised in our country the permanent solution they deserve.

Dreamers are vital to the future of our companies in the Biotechnology Industry. With them, we grow and create jobs. Dreamers are part of why we will continue to have a global competitive advantage and the world’s leading Biotechnology Industry.

Respectfully, and on behalf of all signatories,
 
                                          Steven H. Holtzman                                  Jeremy M. Levin
                                          President & CEO                                      Chairman & CEO
                                          Decibel Therapeutics                                Ovid Therapeutics


Mark Levin, Partner Third Rock Ventures
John Maraganore, CEO Alnylam Pharmaceuticals
George Scangos, CEO Vir Bio
David Schenkein, CEO Agios
Bassil Dahiyat, President & CEO Xencor, Inc.
Paul Sekhri, President & CEO Lycera Corp.
Cedric Francois, President & CEO Apellis Pharmaceuticals
Paula K. Cobb, EVP Corporate Development Decibel Therapeutics
Bernat Olle, CEO Vedanta Biosciences
Robert Nelsen, Co-founder & Managing Director ARCH Venture Partners
Jeb Keiper, CFO & CBO Nimbus Therapeutics
Barry Greene, President Alnylam Pharmaceuticals
Pablo Cagnoni, President & CEO Tizona Therapeutics
Brook Byers, Partner Kleiner Perkins Caufield & Byers
Jean Francois Formela, Partner Atlas Venture
Alex Martin, CEO Realm Therapeutics
Jay Short, CEO BioAtla
David Baltimore, Board member of Biotech firms, Professor of Biology, Caltech and Nobel Laureate in Physiology or Medicine, 1975
Daniel Teper, CEO Cytovia Oncology
Stuart L. Schreiber, Co-Founder Broad Institute
Peter Kolchinsky, Managing Partner RA Capital Management, LLC
Yaron Werber, Chief Business & Financial Officer Ovid Therapeutics
Brian J. G. Pereira, CEO Visterra
Ron Cohen, President & CEO Acorda Therapeutics
Tony Coles, CEO Yumanity
Ted Love, CEO Global Blood Therapeutics
Joel Martin, President & CEO Dauntless Therapeutics
Sandy Zweifach, President & CEO Nuvelution Pharma
Stewart Parker, Principal Parker BioConsulting
Steven Gillis, Partner Arch Venture Partners
Ken Moch, President & CEO Cognition Therapeutics
Jason Rhodes, Partner Atlas Venture
Matthew Perry, President & CEO BVF Partners
Stephen Isaacs, Chairman, President & CEO Aduro Biotech, Inc.
Gerhard Koenig, President & CEO Quartet Medicine
John P. Butler, President & CEO Akebia Therapeutics
Ronald A. DePinho, Past President & Distinguished University Professor, The University of Texas MD Anderson Cancer Center
Rakesh K. Jain, Director E.L. Steele Laboratories, MGH
Nancy Simonian, CEO Syros Pharmaceuticals
Samuel D. Waksal, Founder Kadmon Corporation
William J. Newell, CEO Sutro Biopharma
Nancy A. Thornberry, CEO Kallyope
Amit Rakhit, Chief Medical & Portfolio Officer Ovid Therapeutics
Laurence Reid, CEO Warp Drive Bio
Michael D Clayman, CEO Flexion Therapeutics
William Slattery, Partner Deerfield Management
Bruce A. Leicher, Sr. VP & General Counsel Momenta Pharmaceuticals
Clifford J. Stocks, CEO OncoResponse
Jonathan J. Fleming, President & CEO Q-State Biosciences Corporation
John Osborn, Board Member Egalet Corporation
David S. Block, Chairman & CEO Gliknik Inc.
Perry Karsen, Chair of the Board Intellia Therapeutics
Clay Siegall, CEO Seattle Genetics
Paul Abrams, Chairman Nexgen Medical Systems
Rusty Williams, Chairman & CEO Five Prime Therapeutics
Thomas Shenk, Professor Princeton University
Michel Vounatsos, CEO Biogen
Arthur Tzianabos, President & CEO Homology Medicines
Maxine Gowen, President & CEO Trevena
Rajeev Shah, Managing Dir. & Portfolio Manager RA Capital Management
Chip Clark, CEO Genocea Biosciences
David V. Goeddel, Managing Partner The Column Group
Kleanthis Xanthopoulos, Managing Gen. Partner Cerus Advisors
Emil Kakkis, CEO & President Ultragenyx Pharmaceutical
Hugh O'Dowd, CEO Neon Therapeutics
Hans Bishop, CEO Juno Therapeutics
Alan Crane, Partner & Entrepreneur Polaris Partners
Douglas Doerfler, President & CEO MaxCyte
Camille Samuels, Partner Venrock
Tom Cirrito, CEO Filament BioSolutions
Mark A. Goldsmith, President & CEO REVOLUTION Medicines
Ronald C. Renaud, Jr, CEO Translate Bio
Julia Owens, President & CEO Millendo Therapeutics
Zoe Barry, Founder & CEO ZappRx
Uri Lopatin, CMO Assembly Biosciences
Gail J. Maderis, President & CEO Antiva Biosciences
David R. Liu, Professor Harvard University & Broad Institute
Mara G. Aspinall, CEO Health Catalysts
Patrick J Mahaffy, President & CEO Clovis Oncology
William J. Rieflin, CEO NGM BIO
Otello Stampacchia, Managing Director Omega Funds
Michael Bonney, Chair Alnylam Pharmaceuticals
Lillian Chiang, President & CEO FORGE Life Science
Jeffrey Brewer, President & CEO Bigfoot Biomedical
Jeff Jonker, President NGM Bio
Robert Kamen, Entrepreneur in Residence Third Rock Ventures
Jeff Stein, President & CEO Cidara Therapeutics
Harvey F. Lodish, Member Whitehead Institute for Biomedical Research
Ashley Dombkowski, CEO & Co-founder Before Brands
Paul Laikind, President & CEO ViaCyte
Ailis Tweed-Kent, Founder & CEO Cocoon Biotech
Brian M. Gallagher, Jr, Partner SR One Ltd.
Ryan J. Watts, President & CEO Denali Therapeutics
Paul Bolno, President & CEO Wave Life Sciences
Ankit Mahadevia, CEO Spero Therapeutics
Anna Forsythe, CEO Purple Squirrel Economics
Michael Morrissey, CEO Exelixis
Rob Perez, Founder & Chairman Life Science Cares
Daphne Zohar, Founder & CEO PureTech Health
Martin Tolar, Founder, President & CEO Alzheon
Laura Shawver, CEO Cleave Biosciences
Akshay Vaishnaw, EVP, R&D Alnylam Pharmaceuticals
Bill Rastetter, Chairman & CEO Grail
Rachel King, CEO Glycomimetics
Simba Gill, CEO Evelo Biosciences
Eric Dobmeier, COO Seattle Genetics
Robert I. Blum, President & CEO Cytokinetics
Martin Babler, CEO Principia Biopharma
Hugo Peris, President Spiral Therapeutics
Adam Gridley, President & CEO Histogenics Corporation
Gregory Went, CEO & Chairman Adamas Pharmaceuticals
Neil Kumar, CEO BridgeBio Pharma
Bob Coughlin, CEO MassBio
Paula Ness Spears, Managing Director Health Advances LLC
Mark Speers, Managing Director Health Advances LLC
Andrew Funderburk, Partner Health Advances LLC
Sheela Hegde, Partner Health Advances LLC
Donna Hochberg, Partner Health Advances LLC
Wyatt Gotbetter, Partner Health Advances LLC
Gary Gustavsen, Partner Health Advances LLC
Andrew Matzkin, Partner Health Advances LLC
Vivek Mittal, Partner Health Advances LLC
Susan Posner, Partner Health Advances LLC
Peter Strumph, President & CEO Amygdala Neurosciences
Jeff Behrens, President & CEO Siamab Therapeutics
Michael Gilman, Chairman & CEO Arrakis Therapeutics
Atul Pande, CMO PureTech Health
Robert Forrester, President & CEO Verastem
Marco Taglietti, President & CEO SCYNEXIS
Sean George, CEO Invitae
Andy Palmer, CIO (retired) Infinity Pharmaceuticals
George P. Vlasuk, President & CEO Navitor Pharmaceuticals
Larry Green, Founder & CEO Ablexis
Kia Motesharei, VP & Global Head of BD, N&I Merck KGaA
Mark A. Murcko, CSO Relay Therapeutics
Jeffrey L. Cleland, President & CEO Graybug Vision
Gonul Velicelebi, Founder & CEO Camino Pharma
Melyssa Weible, Managing Partner & Co-Founder Elixir Health PR
Alan Levy, CEO Chrono Therapeutics
Ram Sasisekharan, Professor & Entrepreneur Koch Institute & MIT
Nagesh K. Mahanthappa, President & CEO Scholar Rock
Nima Farzan, CEO PaxVax
Cary G. Pfeffer, Partner Third Rock Ventures
Bob More, General Partner Alta Partners
Mike Powell, General Partner Sofinnova Ventures
Shin-San Michael Su, CSO Decibel Therapeutics
Constance McKee, President & CEO Manzanita Pharmaceuticals
Lynn Hanessian, Chief Strategist Edelman
Sunil Joshi, Managing Director Strategi.us Consulting
Justin Klein, Partner New Enterprise Associates
Laurent Fischer, Former CEO Tobira Therapeutics
Jeffrey Kaplan, Partner Deerfield Management
John Lee, SVP, Pharmaceutical Development Decibel Therapeutics
Nick Galakatos, Co-Founder & Managing Director Clarus Funds
Heather Franklin, President & CEO Blaze Bioscience
Jonathon Leff, Partner Deerfield Management
Jeffrey Jacob, CEO Cancer Prevention Pharmaceuticals
Faheem Hasnain, Chairman Tocagen
Renee Russo, President & CEO Arsanis
H. Robert Horvitz, David H. Koch Professor of Biology, MIT and Nobel Laureate in Physiology or Medicine, 2002
Wendell Wierenga, Chairman Crinetics Pharmaceuticals
Eddie Martucci, Co-Founder & CEO Akili
Neil Exter, Partner Third Rock Ventures
Tim Harris, EVP R&D Bioverativ
Jim Geraghty, Chairman Juniper Pharmaceuticals
Christian V. Kuhlen, General Counsel Ignyta
Hervé Hoppenot, Chairman & CEO Incyte
Tuan Ha-Ngoc, Executive Chairman KEW
Gregory J. Flesher, President & CEO Novus Therapeutics
Julian Adams, CEO Aldila Therapeutics
Deborah Dunsire, CEO XTuit Pharmaceuticals
Vanessa King, Biotech Entrepreneur Atlas Advisor
Douglas E. Williams, President & CEO Codiak BioSciences
Brian M. Cali, Founder & SVP, R&D Strategy and External Innovation Ironwood Pharmaceuticals
Nick Leschly, Chief Bluebird bluebird bio
Scott Koenig, President & CEO MacroGenics
Richard Heyman, Executive Chair Metacrine
Robert Tepper, Partner Third Rock Ventures
Guy Macdonald, CEO Tetraphase
Stephen Sherwin, Clinical Professor of Medicine UCSF
Tanya Shnaydman, Corporate Communications Santen Pharmaceutical
Cigall Kadoch, Scientific Founder Foghorn Therapeutics
Bill Haney, CEO Dragonfly Therapeutics

Comments